2020年7月26日
A Follow-Up Report of an Infant Born to a Mother Receiving Tamoxifen
Case Reports in Pediatrics
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 2020
- 号
- 開始ページ
- 2056756
- 終了ページ
- 2056756
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1155/2020/2056756
Tamoxifen, an estrogen receptor antagonist, is contraindicated in pregnant women due to its teratogenic activity. In the present study, we report the case of an infant whose mother received tamoxifen for breast cancer while unaware of the pregnancy. The infant, born at 29 weeks and 6 days of gestational age with a birth weight of 1664 g, had no congenital anomalies. This case presents detailed information on the development of an infant with placental transfer of tamoxifen. The infant has grown and developed normally throughout a 5-year follow-up period, but long-term vigilance continues.
- リンク情報
- ID情報
-
- DOI : 10.1155/2020/2056756
- ORCIDのPut Code : 77908009
- PubMed ID : 32774971
- PubMed Central 記事ID : PMC7399775